Publications

All trial summaries

Read abstracts below

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD

Lancet. 2009

SPCG-7/FUO3

Abstract

PSA kinetics improved prediction of survival in metastatic hormone-refractory prostate cancer.

Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund PO, Varenhorst E; Scandinavian Prostate Cancer Group.

Urology. 2008

SPCG-5

Abstract

Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE

J Natl Cancer Inst. 2008

SPCG-4

Abstract

Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase.

Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S, Varenhorst, E and the candinavian Prostate Cancer Group (SPCG)-5.

J Urol. 2008

SPCG-5

Abstract

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E and the SPCG-5 Study Group.

Scand J Urol Nephrol. 2008

SPCG-5

Abstract